Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration
Public ClinicalTrials.gov record NCT03372746. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration: An Ancillary Study to the Age-Related Eye Disease Study-2 (AREDS2)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Background: Age-related macular degeneration (AMD) is the leading cause of blindness in the United States. Currently, there is no safe way to obtain cells from the eye to study. But researchers now can turn other types of cells, like skin or blood, into induced pluripotent stem (iPS) cells. These can be grown in a lab and turned into other types of cells, like cells from the eye. This will allow researchers to understand and treat diseases of the eye such as AMD. Objectives: To establish a bank of samples that can be changed into other cell types, such as eye cells, to better understand diseases such as AMD. Also to test drugs in order to treat various eye diseases. Eligibility: People who provided DNA samples in another protocol (07-EI-0025) Design: Participants will be screened with their data from the previous protocol. Participants with select genetic variants will be chosen and contacted via phone. Participants will have a punch skin biopsy. The skin will be washed. A numbing medication will be injected. A small piece of skin will be removed with a biopsy tool. The site will be covered with a dressing. They will receive instructions on how to care for the area. They will have follow-up visits if needed for clinical care for the area. Participants may be asked to return if their first sample did not provide enough cells for the lab. Participants sample will be developed into eye cells. The cells will be used to understand diseases and test new drugs.
Study identification
- NCT ID
- NCT03372746
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 187 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 22, 2018
- Primary completion
- Mar 20, 2019
- Completion
- Mar 20, 2019
- Last update posted
- Apr 4, 2019
2018 – 2019
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Retina-Vitreous Associates Med Group | Beverly Hills | California | 90211 | — |
| Bascom Palmer Eye Institute | Miami | Florida | 33136 | — |
| Emory University Eye Center | Atlanta | Georgia | 30322 | — |
| Retina Vitreous Associates of Kentucky | Lexington | Kentucky | 40509 | — |
| National Institutes of Health Clinical Center | Bethesda | Maryland | 20892 | — |
| Elman Retina Group, P.A. | Rosedale | Maryland | 21237 | — |
| Massachusetts Eye and Ear Infirmary | Boston | Massachusetts | 02114-3096 | — |
| Vision Research ROPARD Foundation/Associated Retinal Consultants, Grand Rapids | Grand Rapids | Michigan | 49546 | — |
| Vision Research ROPARD Foundation/Associated Retinal Consultants, Novi | Novi | Michigan | 48375 | — |
| Charlotte Eye Ear Nose & Throat Associates | Charlotte | North Carolina | 28210 | — |
| Casey Eye Institute | Portland | Oregon | 97210 | — |
| Texas Retina Associates | Dallas | Texas | 75231 | — |
| John Moran Eye Center, University of Utah | Salt Lake City | Utah | 84132 | — |
| University of Wisconsin-Madison | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03372746, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 4, 2019 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03372746 live on ClinicalTrials.gov.